HC Wainwright & Co. Downgrades Inhibikase Therapeutics to Neutral

Benzinga Newsdesk Feb 12, 2025 1 year ago

NewsDowngradesAnalyst Ratings

HC Wainwright & Co. analyst Edward White downgrades Inhibikase Therapeutics (NASDAQ:IKT) from Buy to Neutral.